VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced two additions to its leadership team and one new scientific advisor as follows: Jianmin Duan, PhD, Vice President, Pharmacology…


Previous articlePT241 – Nick Meyers and Tyler Chandler of “Dosed”: Iboga and The Opioid Crisis
Next articleLobe Sciences Enters into Joint Venture with Virtual Psychedelics Incorporated to Develop Multi-Sensory Pods for Clinical Psychedelic Use